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Hepatitis B ﬂare, deﬁned as an event with abrupt rise of alanine
aminotransferase (ALT) levels to >5 times the upper limit of nor-
mal during chronic hepatitis B virus (HBV) infection, is consid-
ered to be the result of a human leukocyte antigen-I restricted,
cytotoxic T lymphocyte mediated immune response against
HBV and its downstream mechanisms. It may occur spontane-
ously, during or after antiviral therapy and in the setting of
immunosuppression and/or chemotherapy. The clinical spectrum
of hepatitis B ﬂares varies from asymptomatic to symptomatic
and typical overt acute hepatitis, even with hepatic decompensa-
tion or failure. Flares may also occur in viraemic patients with cir-
rhosis with higher incidence of decompensation/mortality, hence
requiring immediate antiviral therapy. An upsurge of serum HBV
DNA and hepatitis B surface antigen levels usually precedes the
abrupt rise of ALT levels. Rising or stable and high HBV DNA dur-
ing ﬂares represent ineffective immune clearance and further
hepatocytolysis, even hepatic decompensation, may occur. Such
patients require immediate antiviral therapy. In contrast, bridg-
ing hepatic necrosis and/or alpha-fetoprotein levels >100 ng/ml
or decreasing HBV DNA during ﬂares represent a more effective
immune clearance and frequently leads to seroclearance of HBV
DNA and/or hepatitis B e antigen with remission. If patients are
non-cirrhotic and there is no concern of developing decompensa-
tion, patients may be observed for 3–6 months before deciding on
the need of antiviral therapy. Severe and repeated ﬂares are
prone to develop into decompensation or lead to the develop-Journal of Hepatology 20
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regulatory T cell; ULN, upper limit of normal; TDF, tenofovir.ment of cirrhosis, thus a timely treatment to prevent the hepatitis
B ﬂare is better than to cope with the ﬂare. Screening, monitoring
and prophylactic or pre-emptive antiviral therapy is mandatory
for patients who are going to receive immunosuppressants or
chemotherapy.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Chronic hepatitis B virus (HBV) infection is a dynamic state of
interactions among HBV, hepatocytes and immune cells of the
host. Accordingly, hepatitis activity with alanine aminotransfer-
ase (ALT) elevation and episodic abrupt rise of ALT, so called
acute exacerbation or hepatitis ﬂare, may occur spontaneously
[1]. Hepatitis B ﬂares may also occur during or after antiviral
therapy or in the setting of immunosuppression and/or chemo-
therapy [2]. Based on earlier ﬁndings that less active hepatitis
usually has an ALT level below 5 times the upper limit of normal
(ULN), while active hepatitis has an ALT value far above this level
[3], a chronic hepatitis B (CHB) ﬂare was initially deﬁned as ‘‘an
abrupt elevation of ALT over 300 U/L (normal <40 U/L) in patients
with a baseline ALT level <200 U/L (<5 ULN)’’ [4]. Later, it was
deﬁned as ‘‘an abrupt elevation of serum ALT to >5 ULN or a
greater than 3-fold increase in ALT, whichever was higher’’ [5],
and then as ‘‘intermittent elevations of aminotransferase activity
to more than 10 times ULN and more than twice the baseline
value’’ [6]. All of these deﬁnitions agree that ‘‘an abrupt ALT
elevation >5 ULN’’ is the minimum criterion of a hepatitis ﬂare.
This ALT threshold has been widely accepted in the categorical
analyses of therapeutical trials or clinical studies since 1990s.
Acute superinfection with other hepatitis virus(es) in patients
with chronic HBV infection also presents with an abrupt high rise
of ALT and should be differentiated from the hepatitis ﬂare
caused by HBV (hepatitis B ﬂare) using serologic or virologic
assays [2,3,7].
In recent decades, ultrasensitive assays for serum HBV DNA
and hepatitis B surface antigen (HBsAg) levels as well as new
therapeutic agents have become available. Hence, new advances
in the understanding of the natural history, the immunopatho-
genesis of the hepatitis B ﬂare and its management have emerged.
The following is an update and appraisal of the issues related to14 vol. 61 j 1407–1417
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Fig. 1. Clinical course of a patient with two episodes of hepatitis ﬂare. The
abrupt elevation of serum alanine aminotransferase (ALT) is followed by a rise of
serum alphafetoprotein (AFP), with a time lag of 1–2 weeks between the peak
levels of ALT and AFP. AFP level was low during the ﬂare with lobular hepatitis
(LH) but >100 ng/ml during the (second) ﬂare with bridging hepatic necrosis
(BHN), which was followed by subsequent HBeAg seroconversion to its antibody
(anti-HBe).
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hepatitis B ﬂare, using a diagnostic threshold of ALT >5x ULN. The
superinfection issues are not covered in this review.
Key Points
• Acute hepatitis B flares (ALT >5x ULN) are results of a 
HLA-I restricted, CTL mediated response against HBV. 
Stronger endogenous immune responses result in more 
hepatocytolysis, higher ALT levels and more effective 
clearance of HBV
• Flares with rising and high HBV DNA may lead to 
hepatic decompensation, thus requiring immediate 
antiviral therapy for prevention or rescue
• While flares in cirrhotic patients always require 
immediate antiviral therapy, flares in non-cirrhotic 
patients with decreasing HBV DNA may be followed by 
HBV and/or HBeAg loss with remission, and therefore, 
may be observed for 3-6 months for real indication of 
antiviral therapy
• Severe flares (decompensation, bridging hepatic 
necrosis, AFP >100 ng/ml) are prone to progress to 
cirrhosis, thus timely treatment to prevent the hepatitis 
flare is better than to treat the flare
• Screening, monitoring and prophylactic or pre-emptive 
antiviral therapy is mandatory for patients who are going 
to receive immunosuppressants or chemotherapySpontaneous hepatitis B ﬂare
Clinical and pathological presentations
During the natural course of chronic HBV infection, hepatitis B
ﬂares start to occur during the hepatitis B e antigen (HBeAg) posi-
tive immune clearance phase [1,4,5,8]. Hepatitis B ﬂares also
occur in the HBeAg-negative reactive phase, but less frequently
than during the HBeAg-positive phase [9–11]. In a hospital based
study of CHB, the annual incidence of hepatitis ﬂares was calcu-
lated to be 27% in 358 HBeAg-positive patients and 10% in 279
HBeAg-negative counterparts during a mean follow-up period
of 2 years after entry [9]. It is not uncommon to have multiple
episodic hepatitis B ﬂares in one individual patient [4,8,11].
Clinical presentations
The clinical spectrum of hepatitis B ﬂares varies from totally
asymptomatic to symptomatic and to a feature similar to overt
acute hepatitis (around 30%), with extreme manifestations of
severe ﬂares complicating hepatic decompensation (jaundice
and coagulopathy) or even leading to hepatic failure [8–12].
Some hepatitis B ﬂares may present as overt acute hepatitis, sero-
positive for HBsAg but negative for IgM class antibody to the hep-
atitis B core antigen (IgM anti-HBc) in patients who have had no
past history of HBV infection or liver disease [13]. Hepatitis B
ﬂares may also occur in viraemic CHB patients with cirrhosis,
including those after curative resection of hepatocellular carci-
noma (HCC), and are associated with a higher rate of hepatic
decompensation (13.9% vs. 2–3% in CHB) and mortality than in
those of CHB without cirrhosis [14].1408 Journal of Hepatology 2014Laboratory ﬁndings and AFP level
The biochemical abnormalities, including serum ALT and biliru-
bin, of hepatitis B ﬂares are similar to but in general less severe
than those of acute hepatitis or acute superinfections [3]. Using
enzyme immunoassay, 10–25% of hepatitis B ﬂares were
seropositive for IgM anti-HBc, but usually at a low serum/cut-
off ratio compared to acute hepatitis B [8,11,15]. About 25–30%
of hepatitis B ﬂares are associated with an elevation of serum
alpha-fetoprotein (AFP), of which the peak level is determined
by 3 to 4 weekly or biweekly measurements after the onset of
abrupt ALT elevation (Fig. 1). The peak serum AFP levels usually
appear 1–2 weeks after the peak of ALT and may increase even
over 2500 ng/ml, and usually return to a normal level within
3–12 months after the ﬂare [16]. Of note, HCC should always be
ruled out in patients with any elevated AFP level.Histological ﬁndings
Liver biopsies during hepatitis B ﬂares invariably show lobular
necroinﬂammatory changes, which are distributed unevenly
and may be so extensive that bridging hepatic necrosis (BHN)
may occur [4,8,9]. BHN is evident in more than 80% of the
patients with AFP >100 ng/ml during hepatitis B ﬂares [7]. It
was further demonstrated that patients with high AFP or BHN
during the hepatitis ﬂare had a high degree of AFP-producing oval
cell activation (23.7–25.7% of hepatocytes), in contrast to 2.4–
5.6% in patients with APF <100 ng/ml or no BHN [17]. Therefore,
properly measured AFP-levels during the hepatitis ﬂare of
>100 ng/ml can be used as a surrogate marker of BHN.Pathogenesis of the hepatitis B ﬂare
HBV is not directly cytopathic by itself and the hepatocellular
injuries are considered to be the results of a complex interplay
among HBV, hepatocytes and immune cells of the host [1–4,7].
It has been documented by weekly to monthly assays that there
is an upsurge of serum HBV DNA prior to the abrupt elevation of
ALT [18–20]. There is also a parallel elevation of the serum HBsAg
level along with the upsurge of serum HBV DNA (Fig. 2). Using avol. 61 j 1407–1417
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Fig. 2. Serial serum levels of HBV DNA and hepatitis B surface antigen
(qHBsAg) during a hepatitis B ﬂare. There is a surge of HBV DNA and HBsAg
levels prior to the peak of the abrupt elevation of serum alanine aminotransferase
(ALT) in both hepatitis B e antigen (HBeAg) positive and HBeAg-negative anti-HBe
positive patients.
JOURNAL OF HEPATOLOGYhybridization assay for HBV DNA and a conventional enzyme
immunoassay to measure the HBeAg level, an earlier study
showed signiﬁcant parallel increases in serum HBeAg and HBV
DNA levels and accumulation of intracellular viral proteins
several weeks before the hepatitis ﬂare. In addition, there was a
subsequent increase in anti-HBe production and HBeAg/Table 1. Dynamic changes during hepatitis B ﬂares.
Ascending
HBV DNA Increasing to
HBeAg Increasing to
HBeAg/HBcAg-specific T cell response Increasing
HBV-specific Treg Decline
HBV-specific Tc Increasing
IFN-γ, IL-2 Increasing
IFN-α, IL-8 Increasing to
CXCL-9/CXCL-10 Increasing
IL-10 Increasing to
PD-1/PD-L1 Increasing
ALT, alanine aminotransferase; HBcAg, hepatitis B core antigen; HBeAg, hepatitis B e anti
death protein 1; PD-L1, programmed death-ligand 1; Tc, cytotoxic T cell; Treg, regulato
Journal of Hepatology 2014anti-HBe immune complex formation, implicating the important
role of the immune response to HBV in initiating the hepatitis
ﬂare [21]. Immunohistologic studies during the hepatitis ﬂares
have shown CD8+ T cells in the mononuclear cell inﬁltrates,
strong membranous expression of human leukocyte antigen class
I (HLA-I), and cytoplasmic or membranous/submembranous
hepatitis B core antigen (HBcAg) expression [22,23]. Earlier
immunologic studies showed a 2–4 fold elevation of HBcAg/
HBeAg-speciﬁc precursor T cell frequencies, with an increase of
HBcAg/HBeAg-speciﬁc T cell proliferation before and during the
hepatitis ﬂares [24], an increased production of interferon
gamma (IFN-c) at the time of hepatitis ﬂares [25] and Th1 pheno-
typic cytokines (IL-2 and IFN-c) were upregulated during high
ALT levels [26]. It was demonstrated that an increase in circulat-
ing and intrahepatic IL-17-producing CD4+ T cells correlated well
with ALT level and liver injury [27]. Longitudinal immunologic
studies showed a decline of HBcAg-speciﬁc regulatory T cell
(Treg) frequencies, associated with an increase in HBcAg-speciﬁc
cytotoxic T lymphocyte (CTL) frequencies prior to the peak of the
hepatitis ﬂare [28–30], IL-10-producing regulatory B cell frequen-
cies and serum IL-10 level peaked with the increase in viral load
and decreased at the same time or shortly after the peak of ALT
[31], large ﬂuctuations in serum IFN-a and IL-8 concentrations
with peak levels coinciding with a sharp increase in viral load
preceding the onset of the hepatitis ﬂare, and the increases in
serum IFN-a and IL-8 promoted a pathway for the natural killer
(NK)-cell mediated liver damage [32]. It was also shown that
hepatitis ﬂares were temporarily associated with high serum
levels of INF-c inducible chemokines CXCL-9 and CXCL-10 [33],
and that increase, peak and decline in the levels of the pro-
grammed cell death protein 1 (PD-1) and its ligand PD-L1 went
parallel with the ascend, peak and decline of HBV-speciﬁc T cells
and serum ALT levels [34]. Integrated together (Table 1), these
ﬁndings suggest that hepatitis B ﬂares are the results of dynamic
changes of the innate and adaptive immune responses with HLA-I
restricted, CTL mediated immune cytolysis of HBV antigen(s)
expressing hepatocytes and its downstream apoptotic mecha-
nisms [3,7]. Accordingly, a higher ALT level represents a more
vigorous endogenous immune response against HBV. It is still
not clear, however, what triggers the initiation of the immune
cascade.ALT during hepatitis B flare [Ref.]
Peak Descending 
 peak Increase/decline Decline/stable [18-20]
 peak Increase/decline Decline/stable [21]
Increasing Peak/decline/stable [24]
Nadir Increase [28-30]
Peak Decline [24,28-30,34]
Peak/increasing Peak/decline [25,26]
 peak Peak/decline Decline [32]
Peak Decline [33]
 peak Peak/decline Decline [31]
Peak Decline [34]
gen; HBV, hepatitis B virus; IFN, interferon; IL, interleukin; PD-1, programmed cell
ry T cell.
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Review
Natural course following the hepatitis B ﬂare
Short-term course
CHB patients with a rising ALT levels may develop a hepatitis
ﬂare and those with an ALT >5 ULN may deteriorate to severe
hepatitis or hepatic decompensation. Asian-Paciﬁc guidelines
recommend that such patients should be monitored closely with
weekly or biweekly serum ALT, bilirubin, and prothrombin time
measurements to detect clinical deterioration or hepatic decom-
pensation in time for immediate antiviral therapy for prevention
or rescue [35]. Hepatitis B ﬂares, not complicated with decom-
pensation or mortality, are usually followed by decreasing ALT
to pre-ﬂare levels within one month. Less than 20% of the ﬂares
subside later than 3 months in HBeAg-positive patients [8], but
30% of the ﬂares in HBeAg-negative patients are followed by per-
sistently abnormal ALT [11]. A large study showed that patients
with ALT >5 the ULN at entry had a spontaneous HBeAg
seroclearance rate >50%, and a rate of >60% during the 12 and
18-month follow-up, respectively; in contrast, patients with
ALT <5 ULN at entry had <5% and <10% spontaneous clearance
rates, respectively, at the corresponding time points [36], as
shown in Table 2. Another large study showed that patients with
ALT >5 ULN at entry had a spontaneous HBeAg seroconversion
rate of 51% at 2 years, in contrast to 26% in those with ALT <5
ULN at entry [37]. Collectively, these ﬁndings suggest that
patients with serum ALT >5 ULN are different from those with
serum ALT <5 ULN in terms of the strength of the endogenous
immune response against HBV, and also provide a solid scientiﬁc
basis to set an ALT level >5 ULN as a diagnostic threshold for the
hepatitis ﬂare [3,36].
HBeAg/HBV DNA seroclearance
Given that the very stable covalently closed circular DNA
(cccDNA) in hepatocyte nuclei is reduced by hepatocyte killingTable 2. Hepatitis B ﬂare and spontaneous HBeAg seroclearance.
Spontaneous 
HBeAg seroclearance
[Ref.]
3 mo 12 mo 18 mo
No
ALT <5x ULN <2%a 5%b 8%c [36]*
Yes
ALT
>5x ULN 19%a 50%b 67%c [36]*
5-10x ULN 5%d 45%e 58%f [36]*
>10x ULN 25%d 52%e 70%f [36]*
AFP
>100 ng/ml 31%1 62%2 72%3 [36]*
<100 ng/ml 4%1 15%2 19%3 [36]*
BHN
Yes 67%4 [8]
No 16%4 [8]
Hepatitis flare
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; BHN, bridging hepatic
necrosis; HBeAg, hepatitis B e antigen.
⁄Calculated from the database of reference [36].
Signiﬁcant difference between pairs of percentages with same letters:
a,b,c,d,1,2,3,4p <0.001; ep = 0.304; fp = 0.042.
1410 Journal of Hepatology 2014and further diluted by subsequent regeneration [38], the immune
mediated cytolysis of HBV-containing hepatocytes and the non-
cytolytic actions of CTL-secreted cytokines, including IFN-c and
tumour necrosis factor (TNF)-a, in abolishing HBV gene expres-
sion and replication, may enhance the elimination or suppression
of HBV. Subsequently, HBsAg, HBeAg and/or HBV DNA levels may
decrease (Fig. 3A) and even may lead to HBeAg/HBV DNA
seroclearance or HBeAg seroconversion [3,4,18]. In a short-term
scale, around two thirds of spontaneous HBeAg seroconversions
are preceded by hepatitis B ﬂares in the preceding three months
[4,18]. However, only a few hepatitis B ﬂares are followed by
spontaneous HBeAg/HBV DNA seroclearance within 3 months,
unless the hepatitis B ﬂare is severe enough to cause BHN and/
or AFP elevation over 100 ng/ml [3], as shown in Table 2. The
HBV genotype may also play some role in the pathogenesis of
the hepatitis B ﬂare and its outcomes. A study showed that
HBeAg seroconversion in genotype B HBV-infected patients cor-
related with age at entry but not with maximal ALT level during
the clinical course. In contrast, HBeAg seroconversion in genotype
C HBV-infected patients was much enhanced in patients with a
maximal ALT >5 ULN (vs. ALT <5 ULN, p = 0.03) [39]. Another
study showed that hepatitis ﬂares in genotype B HBV-infected
patients had a signiﬁcantly higher number of IFN-c producing
cells (Th1 response), a lower number of IL-10 producing cell
(Th2 response), and a higher cumulative HBeAg seroconversion
rate, as compared with those in genotype C HBV-infected patients
[40]. These ﬁndings might implicate that genotype C HBV infec-
tion requires more vigorous immune response to achieve viral
clearance and that HBeAg seroconversion occurs earlier and moreB HBeAg (+)
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Fig. 3. Changes of serum alanine aminotransferase (ALT) and HBV DNA in two
hepatitis B e antigen (HBeAg) positive patients with a hepatitis B ﬂare. (A)
Patient A: hepatitis B ﬂare with decreasing HBV DNA prior to the peak of rising
ALT level represents ‘effective immune clearance of HBV’. The patient developed
subsequent spontaneous HBeAg seroconversion. (B) Patient B: hepatitis B ﬂare
with increasing HBV DNA level despite high rise of ALT represents ‘ineffective
immune clearance of HBV’. The patient is at the risk of prolonged activity and
hepatic decompensation requiring immediate antiviral therapy. qHBsAg, quantity
of hepatitis B surface antigen.
vol. 61 j 1407–1417
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frequently in genotype B than in genotype C HBV-infected
patients [39]. Whether other HBV genotypes have such geno-
type-related difference in the hepatitis B ﬂare remains to be
explored.
It is important to note that patients, whose serum HBV DNA is
rising further or not decreasing along with increasing ALT, may
have ineffective (abortive) immune clearance and HBeAg sero-
conversion usually will not follow after the ﬂare (Fig. 3B).
Furthermore, a study showed that HBV DNA >3  108 IU/ml along
with increasing ALT during the hepatitis ﬂare is predictive of
subsequent hepatic decompensation, with a sensitivity and a
speciﬁcity both of 86% and a negative predictive value of 99%
[41]. Such patients as well as cirrhotic patients with hepatitis
ﬂares require immediate anti-HBV therapy. In contrast, patients
whose serum HBV DNA starts to decrease before the ALT peak
may have effective immune clearance, which may lead to HBV
DNA/HBeAg seroclearance and disease remission [3]. The key
difference between effective and ineffective immune clearance
perhaps relies on whether the Th1 response has been enhanced
or not [28,40]. Therefore, if there is no concern about hepatic
decompensation, it is reasonable to observe non-cirrhotic
patients with hepatitis B ﬂares for 3–6 months to see whether
antiviral therapy is indeed needed [35].
Longer-term outcomes
Spontaneous HBeAg seroconversion or HBV DNA suppression
with sustained remission usually occurs after multiple episodes
of hepatitis ﬂares. Patients who fail to clear HBeAg and/or HBV
DNA after a hepatitis B ﬂare may have normal ALT for a variable
duration, and the hepatitis B ﬂare may recur afterwards due to
reactivation of the original HBV pool and may re-emerge
repeatedly until HBV is suppressed to an inactive level
(HBeAg-negative, ALT normal and HBV DNA <2000 IU/ml). Those
who underwent spontaneous HBeAg seroconversion before age
30 have a much lower 15-year cumulative incidence of HBeAg-
negative hepatitis and low 15-year incidence of cirrhosis (3.7%)
or HCC (2.1%) [42]. Besides age of the patient and age at HBeAg
seroconversion, studies have shown that severe hepatitis B ﬂares
with hepatic decompensation or more extensive hepatocytolysis
with BHN or AFP >100 ng/ml, especially if occurring repeatedly
(repeated BHN or repeated AFP >100 ng/ml) or if ﬂares are not
followed by ALT normalization or go along with delayed HBeAg/
HBV DNA seroclearance over 40 year of age, are prone to develop
into liver cirrhosis [42,43]. Flares due to HBeAg sero-reversion
are also a factor for progression to liver cirrhosis [43].
Since more severe hepatitis B ﬂares may be complicated
with hepatic decompensation and have an increased risk of cir-
rhosis development, it is conceivably to better prevent their
occurrence than to contend with the hepatitis B ﬂare. Therefore,
all HBsAg-positive subjects should be monitored and treated
timely before the hepatitis B ﬂare has occurred [35]. Patients
with hepatitis B ﬂare who fail to clear HBV, especially those
with BHN or AFP >100 ng/ml, need more aggressive antiviral
therapy.Antiviral therapy related hepatitis B ﬂares
Hepatitis B ﬂares are not uncommon during and after withdrawal
of antiviral therapy in patients with CHB with or without
cirrhosis.Journal of Hepatology 2014Interferon based therapy
Conventional interferon-a (IFN-a)
The best known example of a hepatitis ﬂare in relation to drug
therapy is the one associated with IFN-a therapy or following
withdrawal of a short course of corticosteroids prior to IFN-a
therapy. IFN may increase T cell activity and NK cell function
and hence, may induce a hepatitis ﬂare. A study showed that
the hepatitis ﬂare developed typically during the second to third
month of therapy in 45–49% of the patients treated with conven-
tional IFN-a and in 71% of the patients treated with IFN-a after
prednisolone withdrawal. The study further showed that the hep-
atitis ﬂare was an independent predictor and an ALT increase
>344 U/L was the most powerful predictor of a sustained
response [44]. It was shown that the hepatitis ﬂare followed by
IL-12 elevation with a signiﬁcant subsequent rise in Th1 cyto-
kines (IFNc and IL-2) was important for HBeAg seroconversion,
associated with IFN-a therapy [45].
Pegylated IFN- (Peg IFN)
Hepatitis ﬂares were also observed during or after Peg IFN ther-
apy. ALT elevation over 5 times baseline level were reported in
only 5–6% of the HBeAg-positive patients treated with 48-weeks
Peg IFNa-2a, not signiﬁcantly higher than 4% in the lamivudine
(LAM) treated control group [46]. ALT ﬂare >10 ULN was
observed in 12% of HBeAg-negative patients treated with 48-
week Peg IFNa-2a vs. 6% in LAM treated controls [47]. Hepatitis
ﬂares with ALT >5 ULN were observed in around 30% of our
HBeAg-positive and 22% of the HBeAg-negative patients during
48–52 weeks of Peg IFNa-2a therapy (Liaw 2014, unpublished
data). Of the 266 patients treated with Peg IFNa-2b, 25% encoun-
tered a hepatitis ﬂare with a median ALT peak of 12.3 ULN
(60), half during the 52 weeks of therapy and half during
the 26 weeks of follow-up. Among these hepatitis ﬂares, those
followed by a HBV DNA decline P1 log within 4 months were
associated with a high rate of HBeAg loss (58%) and HBsAg loss
(33%), in contrast to 20% and 0%, respectively of ﬂares preceded
by a HBV DNA increaseP1 log within prior 4 months [48]. These
contrasting features and response outcomes are compatible with
the contrast between effective and ineffective immune clearance
in spontaneous hepatitis B ﬂares (Fig. 3).
Though not a head to head comparison, the results of these
studies show that the incidence of a hepatitis ﬂare related to
one year of Peg IFN therapy varies among studies, possibly due
to different clinical features, such as HBV genotype, baseline viral
load and ALT levels of the study patients. Even the highest inci-
dence of hepatitis ﬂares (30%) among the Peg IFN studies is lower
than that (up to 50%) related to 4–6 months of conventional IFN
therapy. The reason(s) for this difference are not known. Given
that Peg IFN is superior in efﬁcacy to conventional IFN in CHB
[49], perhaps Peg IFN may have more effective mechanism(s)
other than its immunomodulatory effect so that immune medi-
ated hepatitis ﬂares are less needed for a better response. Recent
studies do suggest that the efﬁcacy of Peg IFN may be not related
to its potent effects on NK cells [50] and that it may target the
epigenetic regulation of the nuclear cccDNA minichromosome
by antiviral cytokines [51] or induce a speciﬁc non-hepatotoxic
degradation of nuclear HBV cccDNA [52]. In addition, compared
to conventional IFN, Peg IFN induced a longer-lasting effect on
the human interferon-stimulated gene expression without
involvement of the immune cell response [53].vol. 61 j 1407–1417 1411
Table 3. Hepatitis B ﬂare during and after oral antiviral therapy.
HBeAg status During therapy 1-yr off-therapy [Ref.]
>5x ULN >10x ULN >5x ULN >10x ULN
LAM Positive 17% 6% 12% 7% [55]
Positive and negative n.a.
n.a.
6%
9-12%
n.a.
n.a.
n.a.
n.a.
[62]
[63,64]
Negative 3% 2-6% 29% 11% [47,61]
ADV Positive 21% 10% 24% n.a. [57,60]
Positive and negative 3% 2% n.a. n.a. [65]
Negative n.a. n.a. n.a. 33% [58]
LdT Positive and negative n.a.
n.a.
4%
5-6%
n.a.
n.a.
n.a.
n.a.
[62]
[63,64]
ETV Positive 10% 3% 2% 1% [59]
Negative 2% <1% 12% 8% [61]
TDF Positive and negative 6% 3% n.a. n.a. [65]
ADV, adefovir; ETV, entecavir; LAM, lamivudine; LdT, telbivudine; HBeAg, hepatitis B e antigen; n.a., not available; TDF, tenofovir; ULN, upper limit of normal.
ReviewOral antiviral therapy
Pretherapy hepatitis B ﬂares
Under therapy with nucleos(t)ide analogues (Nucs), which have
no direct immunomodulating effects, patients with pretherapy
ALT levels >5 ULN have the highest response rate, suggesting
that patients with a stronger endogenous immune response
against HBV have enhanced their response to direct antivirals
by hepatocytes killing and regeneration leading to reduce cccDNA
[54,55]. Along this line, it was also documented that withdrawal
of a short course of steroid enhanced the host Th1 response and
induced a hepatitis B ﬂare with enhanced response to lamivudine
(LAM) [56].
Hepatitis ﬂares during Nuc therapy
A hepatitis ﬂare with an ALT increase >10x ULN may occur in up
to 10% of patients, being higher in HBeAg-positive patients and
lower under therapy with the more potent Nucs entecavir
(ETV) or tenofovir (TDF) [57–65], as shown in Table 3. Such ﬂares
are not associated with bilirubin increase or hepatic decompen-
sation and usually occur in association with a reduction in serum
HBV DNA levels by >2 log copies/ml within 8 weeks of Nuc
therapy [59,61,65], compatible with the notion that these ﬂares
are the results of a transient restoration of HBV-speciﬁc T cell
responses [66,67].
Hepatitis ﬂares following emergence of drug resistance
Hepatitis B ﬂares that occur after 24 weeks of Nuc therapy are
usually caused by drug resistance. Following an upsurge of
drug-resistant HBV viraemia during continuing Nuc therapy,
ALT increases gradually and may even lead to a hepatitis ﬂare,
decompensation or liver failure [3,68]. During 12 months of
continuous LAM therapy after emergence of LAM resistance in a
series of 66 patients, 44 (67%) developed a hepatitis ﬂare with
ALT >5 ULN, 26 (39%) with ALT >10 ULN, and 9 (14%) were
associated with a serum bilirubin >2 mg/dl, 7 (11%) developed
decompensation and 11 (19%) out of 57 HBeAg-positive patients
seroconverted to anti-HBe [69]. Timely rescue therapy using Nucs
with a different resistance proﬁle can prevent or rescue patients
with a drug resistance-induced hepatitis ﬂare or decompensation
[35,70]. Drug resistance is no more an issue during therapy with1412 Journal of Hepatology 2014ETV or TDF but LAM is still widely used in low resource regions
[71].
Hepatitis B ﬂares after withdrawal of Nuc therapy
In contrary to a hepatitis B ﬂare associated with HBV suppression
during Nuc therapy, hepatitis ﬂares after cessation of Nuc therapy
are preceded by an increase in serum HBV DNA as HBV replica-
tion returns [3,72]. The temporal relationship between HBV
DNA and ALT levels is similar to that during spontaneous hepati-
tis B ﬂares [33]. The off-therapy ﬂares are also similar to sponta-
neous hepatitis ﬂares in the spectrum of clinical presentation that
hepatic decompensation and fatality may occur if not retreated in
time [72–75]. Hepatitis ﬂares may occur after cessation of Nuc
therapy in the majority of the patients who remained HBeAg-
positive [55,75]. Even in patients who underwent HBeAg sero-
conversion during Nuc therapy, hepatitis ﬂares with or without
HBeAg reversion may occur, especially in older patients, those
infected with genotype C HBV, and if the consolidation duration
of therapy is not long enough [76–78].
Virologic relapse (HBV DNA >2000 IU/ml) after cessation of
Nuc therapy is even more frequent in HBeAg-negative patients.
Clinical relapse (HBV DNA >2000 IU/ml with ALT >1.2–2 ULN)
was reported to be 76% after withdrawal of long-term adefovir
(ADV) therapy [79], but was only 43% after ETV cessation [74].
The relapses mostly occurred within 6 months after cessation of
LAM or ADV but more than 6 months after stopping ETV [74].
Hepatitis ﬂares with ALT >5 ULN occurred in 21% of the 33
patients within one year after ADV withdrawal and ALT subsided
spontaneously in most of the patients who were not retreated,
with increasing HBsAg seroclearance over time [79]. Hepatitis
with hepatic decompensation only occurs in those not monitored
or who did not resume Nuc therapy in time [74]. Therefore,
proper off-therapy monitoring is mandatory after cessation of
Nuc therapy.Hepatitis B ﬂares associated with immune restoration
As an immune-mediated disease entity, immunosuppression and
immune restoration may inﬂuence the clinical course and result
in a hepatitis ﬂare in patients with chronic HBV infection.vol. 61 j 1407–1417
JOURNAL OF HEPATOLOGY
Hepatitis B ﬂares in pregnant women
Pregnant women have mechanisms that prevent rejection of the
baby by the maternal immune system, including an increase in
corticosteroids [80]. A study in mothers with chronic HBV infec-
tion showed that serum HBV DNA increased while ALT decreased
signiﬁcantly during pregnancy and that ALT levels increased to
1.8–13.2 the ULN with a decline in serum HBV DNA within
6 months after delivery. The study further showed that women
who received Nuc therapy during the third trimester for preven-
tion of perinatal HBV transmission had a higher chance (62% vs.
36%) of a signiﬁcant increase in liver disease activity [81].
Another study showed that a postpartum ﬂare (ALT >5 ULN)
usually occurred 8–10 weeks after delivery, and was observed
in 50% of the mothers with postpartum Nuc therapy 64 weeks
vs. 40% of those with postpartum Nuc therapy >4 weeks [82].
The postpartum ﬂares were usually mild and resolved spontane-
ously [81,82]. In addition, an age-HBeAg status matched control
study showed that pregnant women had a higher chance of a
postpartum ALT rise (50 vs. 11%; p = 0.01) and HBeAg loss
(14.3% vs. 2.2%; p = 0.02) compared with controls during the same
duration (10–12 months after entry) of follow-up [83]. It is there-
fore important to follow postpartum mothers closely for at least
6 months, especially those who are HBeAg-positive or have
stopped Nuc therapy, and then to continue follow-up as for
ordinary subjects with chronic HBV infection. Hepatitis and
hepatitis B ﬂares occurring in women of childbearing age or ﬂares
related to pregnancy require proper management or antiviral
therapy according to the guidelines [35,70].
Hepatitis B ﬂares in HBV/HIV coinfected patients
Hepatitis B ﬂares during active antiretroviral therapy (ART) in HBV
andhuman immunodeﬁciency virus (HIV) coinfectedpatientsmay
be a consequence of immune restoration with a robust increase in
CD4 cell count in the presence of high HBV load [84]. A prospective
study after the initiation of HBV-active-ART inHIV/HBV coinfected
patients showed that 8 (22%) of 36 patients developed hepatitis B
ﬂares with ALT >5 ULN at week 8 of therapy in association with
increased plasma levels of immune mediators of elevated Th1
response, enhanced T cell activation and monocyte recruitment
[85]. TDF is active against both HBV and HIV and can be used to
treat such ﬂares or as part of a highly active ART [35].
Hepatitis B ﬂares during anti-TB therapy
In HBV endemic regions, tuberculosis (TB) is not uncommon. A
study from Taiwan showed that 15 out of 42 patients who devel-
oped symptomatic hepatitis during anti-TB therapy were HBsAg-
positive and 11 of them were seropositive for HBV DNA (spot
hybridization assay) with late onset hepatitis (110 ± 62 days,
73% >2 months vs. 52 ± 56 days and 26% in HBsAg-negative
counterparts; p <0.005), which was likely following immune
restoration [86]. It is mandatory to monitor HBsAg-positive
patients during anti-TB therapy for timely antiviral therapy.Hepatitis B ﬂares in patients with immuno/chemotherapy
Chemotherapy with or without corticosteroids
Back in 1991, it was reported that reactivation of HBV replication
with icteric hepatitis occurred in 22% of HBsAg-positive patientsJournal of Hepatology 2014and in 2% of anti-HBc and/or anti-HBs positive patients with
malignant lymphoma receiving chemotherapy, and that HBV
reactivation-related liver failure occurred in 7% and 2%, respec-
tively [87]. However, it had not caused due attention until the
early 2000s when prevention of HBV reactivation in this setting
became available [88]. Now, it is well recognized that immuno-
suppression or chemotherapy for haematologic or other solid
tumours as well as stem cell or solid organ transplantation in
patients with chronic HBV infection or with occult HBV infection
is associated with an increased risk of HBV reactivation, with
increasing serum HBV DNA during immunosuppressive/chemo-
therapy, followed by ALT elevation in between therapy adminis-
trations or after the end of the therapy, and that the hepatitis B
ﬂare which may occur can even lead to hepatic decompensation
or fatality [89]. Hepatitis B ﬂares may also occur following tran-
sarterial chemoembolization for HCC in 30% of the patients
[90]. A systemic review of 14 studies (2 randomized, controlled
trials) showed that the pooled incidence of HBV related hepatitis,
liver failure, and mortality was 33.4%, 13%, and 6.7%, respectively.
In contrast, prophylactic LAM therapy reduced the corresponding
incidence to 4%, 0%, and 2%, respectively [91]. Addition of cortico-
steroid in the regimen of chemotherapy may increase the risk and
severity of HBV reactivation. A randomized control trial showed a
2-fold increase in the incidence of HBV reactivation and hepatitis
B ﬂare, and a 3-fold increase in hepatitis B ﬂares with ALT >10
ULN in patients who received prednisolone [92].Anti-CD20
Addition of B cell depleting monoclonal antibodies against CD20
(anti-CD20) such as rituximab in the chemotherapy regimen
increased the risk and severity of HBV reactivation even more,
also in HBsAg-negative anti-HBc positive patients, including
those that are combined seropositive for anti-HBs [93]. A most
recent prospective study in 150 HBsAg-negative anti-HBc posi-
tive patients, undergoing cyclic chemotherapy including ritux-
imab for lymphoma, showed an incidence of HBV reactivation
and hepatitis ﬂare (3-fold increase in ALT and >100 U/L) of
10.4% and 6.4%, respectively, which occurred during or after rit-
uximab-CHOP therapy. With ETV therapy started at the detection
of HBV reactivation, no HBV-related hepatic failure or mortality
occurred [94].Anti-TNF
Since the introduction of anti-TNF agents such as inﬂiximab for
the treatment of rheumatoid arthritis or inﬂammatory bowel dis-
ease and psoriasis, hepatitis B reactivation, hepatitis ﬂares and
death have been reported sporadically. A systemic analysis of
case reports during a mean follow-up of 14 months showed that
HBV reactivation occurred during anti-TNF therapy in 35 (39%) of
89 HBsAg-positive patients and hepatitis B ﬂares (ALT >5 ULN)
occurred in 12 (34%) of the 35 patients with 5 developing liver
failure. The corresponding rates in 168 HBsAg-negative anti-
HBc-positive patients was 7-fold lower than in HBsAg-positive
patients. The risk was signiﬁcantly reduced (23% vs. 62%,
p = 0.003) in those who received antiviral prophylaxis [95].
Currently, there is a universal consensus that it is mandatory
to screen the HBsAg and anti-HBc status for all patients who are
going to receive immunosuppression or chemotherapy and start
prophylactic or pre-emptive antiviral therapy, preferably usingvol. 61 j 1407–1417 1413
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Fig. 4. A decision tree for patients with chronic hepatitis B virus (HBV) infection, including patients with hepatitis B ﬂares (ALT >5 ULN). Follow-up tests of patients
with increasing ALT or ALT >5 ULN include serum bilirubin, alpha-fetoprotein and prothrombin time. ALT, alanine aminotransferase; ASAP, as soon as possible; CHB,
chronic hepatitis B; Fu, follow-up; HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; HD, hepatic decompensation; IFN, interferon; mo, month; Nuc,
nucleos(t)ide analogue; p.r.n, if necessary; ULN, upper limit of normal; wk, week; y, year of age.
ReviewETV or TDF, to prevent HBV reactivation, hepatitis ﬂares and seri-
ous complications [35,70,89,96].Implications and perspectives
In summary, episodic hepatitis B ﬂares with ALT >5 ULN are not
uncommon in patients with chronic HBV infection. ALT/hepatitis
ﬂares are the results of HLA-I restricted, CTL-mediated immune
responses against HBV. Thus, higher ALT reﬂects more vigorous
immune-mediated hepatocytolysis and is associated with stron-
ger clearance of HBV and a higher chance of HBeAg loss and/or
HBV DNA seroclearance, both in the setting of the natural course
of infection and related to drug therapy. While ﬂares in cirrhotic
patients always require immediate antiviral therapy, ﬂares with
decreasing serum HBV DNA levels represent effective immune
clearance of HBV that is likely to be followed by spontaneous
HBeAg/HBV DNA seroconversion or seroclearance (Fig. 3A); thus,
such patients may wait for 3–6 months to see whether drug ther-
apy is needed. In contrast, hepatitis B ﬂares with stable or
increasing serum HBV DNA levels reﬂect ineffective immune
clearance of HBV so that the patients are at risk of further hepat-
ocytolysis or recurrent hepatitis B ﬂare(s) and even hepatic
decompensation, which requires timely treatment (Fig. 3B). In
addition to the immediate risk of hepatic decompensation, more1414 Journal of Hepatology 2014than one severe hepatitis ﬂare is a factor for future development
of liver cirrhosis. Therefore, patients with ALT levels of 2–5 ULN
who have a low chance of spontaneous HBV clearance should be
considered for anti-HBV therapy to stop further liver injuries and
to prevent hepatitis B ﬂares and their adverse sequelae. These
management decisions are summarised in a decision tree
(Fig. 4). Proper monitoring is required in patients who stopped
antiviral therapy. In the setting of anti-HBV therapy, hepatitis B
ﬂares before, during and even after therapy are beneﬁcial in
terms of better response to therapy. Along this line, inducing a
hepatitis ﬂare by priming with a short course of corticosteroid
or Nuc therapy before planned anti-HBV therapy was reported
in small studies. However, the beneﬁt should be weighed against
the risk of an adverse hepatitis B ﬂare. Screening, monitoring and
prophylaxis or pre-emptive anti-HBV therapy is mandatory in
hepatitis B patients who are going to receive immunosuppression
or cancer chemotherapy. In addition, HCC surveillance is also
mandatory in all hepatitis B patients at risk.Financial support
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